Thermosensitive liposomes and localised hyperthermia - An effective bimodality approach for tumour management

B. Tiwari Sandip, N. Udupa, B. S S Rao, P. Uma Devi

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Objectives: To entrap methotrexate (MTX) in thermosensitive liposomes, to characterise liposomes for different physicochemical properties and to investigate the potential of liposome entrapped MTX and localised hyperthermia (HT) in management of melanoma B16F1. Methods: Thermosensitive liposomes, made of synthetic lipids (distearoylphosphatidylcholine, DSPC and dipalmitoylphosphatidylcholine, DPPC) showing gel to liquid phase transition at 41°C, were used for encapsulation of methotrexate. The liposomes were prepared by reverse phase evaporation method. The entrapment efficiency of the drug within the liposomes was determined by gel filtration on Sephadex G-50 column. The in vitro release studies of the vesicles were conducted by incubating the drug encapsulated liposomes in saline at various temperatures for 15 min. The vesicle stability was assessed by storage at room temperature, 37°C and under refrigeration (4°C) for a period of three months. The MTX containing liposomes were administered intravenously to C57BL/6J mice bearing melanoma B16F1 tumour at 12 mg kg-1 dose. Immediately after the drug administration, localised hyperthermia treatment was applied by placing the tumours in water bath at 43°C either for 30 min. or 1 hr. The volume doubling time and growth delay of the tumour were taken as parameters to assess the antitumour efficacy. Results: The thermosensitive liposomes encapsulated about 52% of the MTX. Comparison of the drug release profile at various temperatures revealed that maximum drug release (83%) occurred at 42°C compared to less than 5% release at 37°C. Better stability on storage was also observed with thermosensitive MTX liposomes. The thermosensitive liposomes and localised hyperthermia produced an improved anticancer activity as evident by enhanced volume doubling time and growth delay. Conclusion: These results suggest that localised hyperthermia in combination with temperature sensitive liposome encapsulated MTX may serve as a useful targeted drug delivery system for more effective management of melanoma B16F1.

Original languageEnglish
Pages (from-to)214-220
Number of pages7
JournalIndian Journal of Pharmacology
Volume32
Issue number3
Publication statusPublished - 06-2000

Fingerprint

Liposomes
Fever
Methotrexate
Neoplasms
Melanoma
Temperature
Pharmaceutical Preparations
1,2-Dipalmitoylphosphatidylcholine
Refrigeration
Phase Transition
Drug Delivery Systems
Growth
Baths
Inbred C57BL Mouse
Gel Chromatography
Gels
Lipids
Water

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

@article{ee622ac1b3fd435a818a279c388e6aee,
title = "Thermosensitive liposomes and localised hyperthermia - An effective bimodality approach for tumour management",
abstract = "Objectives: To entrap methotrexate (MTX) in thermosensitive liposomes, to characterise liposomes for different physicochemical properties and to investigate the potential of liposome entrapped MTX and localised hyperthermia (HT) in management of melanoma B16F1. Methods: Thermosensitive liposomes, made of synthetic lipids (distearoylphosphatidylcholine, DSPC and dipalmitoylphosphatidylcholine, DPPC) showing gel to liquid phase transition at 41°C, were used for encapsulation of methotrexate. The liposomes were prepared by reverse phase evaporation method. The entrapment efficiency of the drug within the liposomes was determined by gel filtration on Sephadex G-50 column. The in vitro release studies of the vesicles were conducted by incubating the drug encapsulated liposomes in saline at various temperatures for 15 min. The vesicle stability was assessed by storage at room temperature, 37°C and under refrigeration (4°C) for a period of three months. The MTX containing liposomes were administered intravenously to C57BL/6J mice bearing melanoma B16F1 tumour at 12 mg kg-1 dose. Immediately after the drug administration, localised hyperthermia treatment was applied by placing the tumours in water bath at 43°C either for 30 min. or 1 hr. The volume doubling time and growth delay of the tumour were taken as parameters to assess the antitumour efficacy. Results: The thermosensitive liposomes encapsulated about 52{\%} of the MTX. Comparison of the drug release profile at various temperatures revealed that maximum drug release (83{\%}) occurred at 42°C compared to less than 5{\%} release at 37°C. Better stability on storage was also observed with thermosensitive MTX liposomes. The thermosensitive liposomes and localised hyperthermia produced an improved anticancer activity as evident by enhanced volume doubling time and growth delay. Conclusion: These results suggest that localised hyperthermia in combination with temperature sensitive liposome encapsulated MTX may serve as a useful targeted drug delivery system for more effective management of melanoma B16F1.",
author = "{Tiwari Sandip}, B. and N. Udupa and Rao, {B. S S} and {Uma Devi}, P.",
year = "2000",
month = "6",
language = "English",
volume = "32",
pages = "214--220",
journal = "Indian Journal of Pharmacology",
issn = "0253-7613",
publisher = "Medknow Publications and Media Pvt. Ltd",
number = "3",

}

Thermosensitive liposomes and localised hyperthermia - An effective bimodality approach for tumour management. / Tiwari Sandip, B.; Udupa, N.; Rao, B. S S; Uma Devi, P.

In: Indian Journal of Pharmacology, Vol. 32, No. 3, 06.2000, p. 214-220.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Thermosensitive liposomes and localised hyperthermia - An effective bimodality approach for tumour management

AU - Tiwari Sandip, B.

AU - Udupa, N.

AU - Rao, B. S S

AU - Uma Devi, P.

PY - 2000/6

Y1 - 2000/6

N2 - Objectives: To entrap methotrexate (MTX) in thermosensitive liposomes, to characterise liposomes for different physicochemical properties and to investigate the potential of liposome entrapped MTX and localised hyperthermia (HT) in management of melanoma B16F1. Methods: Thermosensitive liposomes, made of synthetic lipids (distearoylphosphatidylcholine, DSPC and dipalmitoylphosphatidylcholine, DPPC) showing gel to liquid phase transition at 41°C, were used for encapsulation of methotrexate. The liposomes were prepared by reverse phase evaporation method. The entrapment efficiency of the drug within the liposomes was determined by gel filtration on Sephadex G-50 column. The in vitro release studies of the vesicles were conducted by incubating the drug encapsulated liposomes in saline at various temperatures for 15 min. The vesicle stability was assessed by storage at room temperature, 37°C and under refrigeration (4°C) for a period of three months. The MTX containing liposomes were administered intravenously to C57BL/6J mice bearing melanoma B16F1 tumour at 12 mg kg-1 dose. Immediately after the drug administration, localised hyperthermia treatment was applied by placing the tumours in water bath at 43°C either for 30 min. or 1 hr. The volume doubling time and growth delay of the tumour were taken as parameters to assess the antitumour efficacy. Results: The thermosensitive liposomes encapsulated about 52% of the MTX. Comparison of the drug release profile at various temperatures revealed that maximum drug release (83%) occurred at 42°C compared to less than 5% release at 37°C. Better stability on storage was also observed with thermosensitive MTX liposomes. The thermosensitive liposomes and localised hyperthermia produced an improved anticancer activity as evident by enhanced volume doubling time and growth delay. Conclusion: These results suggest that localised hyperthermia in combination with temperature sensitive liposome encapsulated MTX may serve as a useful targeted drug delivery system for more effective management of melanoma B16F1.

AB - Objectives: To entrap methotrexate (MTX) in thermosensitive liposomes, to characterise liposomes for different physicochemical properties and to investigate the potential of liposome entrapped MTX and localised hyperthermia (HT) in management of melanoma B16F1. Methods: Thermosensitive liposomes, made of synthetic lipids (distearoylphosphatidylcholine, DSPC and dipalmitoylphosphatidylcholine, DPPC) showing gel to liquid phase transition at 41°C, were used for encapsulation of methotrexate. The liposomes were prepared by reverse phase evaporation method. The entrapment efficiency of the drug within the liposomes was determined by gel filtration on Sephadex G-50 column. The in vitro release studies of the vesicles were conducted by incubating the drug encapsulated liposomes in saline at various temperatures for 15 min. The vesicle stability was assessed by storage at room temperature, 37°C and under refrigeration (4°C) for a period of three months. The MTX containing liposomes were administered intravenously to C57BL/6J mice bearing melanoma B16F1 tumour at 12 mg kg-1 dose. Immediately after the drug administration, localised hyperthermia treatment was applied by placing the tumours in water bath at 43°C either for 30 min. or 1 hr. The volume doubling time and growth delay of the tumour were taken as parameters to assess the antitumour efficacy. Results: The thermosensitive liposomes encapsulated about 52% of the MTX. Comparison of the drug release profile at various temperatures revealed that maximum drug release (83%) occurred at 42°C compared to less than 5% release at 37°C. Better stability on storage was also observed with thermosensitive MTX liposomes. The thermosensitive liposomes and localised hyperthermia produced an improved anticancer activity as evident by enhanced volume doubling time and growth delay. Conclusion: These results suggest that localised hyperthermia in combination with temperature sensitive liposome encapsulated MTX may serve as a useful targeted drug delivery system for more effective management of melanoma B16F1.

UR - http://www.scopus.com/inward/record.url?scp=0033932547&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033932547&partnerID=8YFLogxK

M3 - Article

VL - 32

SP - 214

EP - 220

JO - Indian Journal of Pharmacology

JF - Indian Journal of Pharmacology

SN - 0253-7613

IS - 3

ER -